Edition:
United States

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

5.30USD
15 Dec 2017
Change (% chg)

$-0.15 (-2.75%)
Prev Close
$5.45
Open
$5.51
Day's High
$5.54
Day's Low
$5.28
Volume
2,160,046
Avg. Vol
423,595
52-wk High
$27.93
52-wk Low
$4.60

Latest Key Developments (Source: Significant Developments)

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Wednesday, 6 Dec 2017 05:23pm EST 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Thursday, 2 Nov 2017 04:30pm EDT 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Axovant Sciences Ltd :At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition.Axovant Sciences - ‍announced that phase 3 mindset clinical trial of its investigational drug intepirdine did not meet its co-primary efficacy endpoints​.Axovant Sciences Ltd - ‍in study, intepirdine was generally well tolerated​.Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia remains on track to report topline results at end of 2017​.Axovant Sciences - ‍after 24 weeks of treatment, change from baseline in cognition was non-significantly improved in intepirdine arm versus placebo arm​.Axovant Sciences Ltd - ‍there was essentially no difference between intepirdine and placebo arms in change from baseline in activities of daily living​.Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia with lewy bodies remains on track to report topline results at end of 2017​.Axovant Sciences - ‍only endpoint in which any significant improvement was seen in intepirdine arm versus placebo arm was in first key secondary endpoint​.Axovant Sciences Ltd - ‍company will work with investigators to conclude mindset open-label extension study​.  Full Article

Axovant to move stock exchange listing to Nasdaq
Monday, 21 Aug 2017 04:15pm EDT 

Aug 21 (Reuters) - Axovant Sciences Ltd :Axovant to move stock exchange listing to Nasdaq.Axovant Sciences Ltd says it will voluntarily move its stock exchange listing from New York Stock Exchange to Nasdaq Global Select Market.Axovant Sciences Ltd - ‍Move is expected to become effective on or about September 6, 2017​.Axovant Sciences Ltd - ‍Company's common shares will continue to trade under ticker symbol "AXON."​.  Full Article

Axovant Sciences reports Q1 loss per share of $0.65
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Axovant Sciences Ltd :Axovant announces fiscal first quarter financial results and corporate updates.Q1 loss per share $0.65.Q1 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.  Full Article

Dermavant Sciences names Celgene's ex-COO Jacqualyn fouse executive chairman
Monday, 10 Jul 2017 08:45am EDT 

July 10 (Reuters) - Dermavant Sciences-:Dermavant Sciences appoints Dr. Jacqualyn Fouse as executive chairman.Dermavant Sciences - ‍fouse recently served as president and COO of Celgene Corp​.  Full Article

Axovant Sciences' Q4 loss per share $0.53
Tuesday, 13 Jun 2017 07:00am EDT 

June 13 (Reuters) - Axovant Sciences Ltd :Axovant Sciences announces fiscal year-end financial results and corporate updates.Q4 loss per share $0.53.Q4 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Expects to meet with U.S. Food and Drug Administration to discuss additional studies that could support registration of RVT-103.Axovant Sciences Ltd says expects to initiate a proof of concept study for RVT-104 in second half of 2017.  Full Article

Axovant Sciences announces pricing of $125 mln public offering of common shares
Tuesday, 11 Apr 2017 07:00am EDT 

Axovant Sciences Ltd : Axovant sciences ltd. Announces pricing of $125m public offering of common shares .Says public offering of 6.74 million common shares priced at $18.54per share.  Full Article

Axovant Sciences Ltd announces $100 million public offering of common shares
Monday, 10 Apr 2017 04:05pm EDT 

Axovant Sciences Ltd :Axovant Sciences Ltd announces $100 million public offering of common shares.  Full Article

Axovant Sciences appoints David Hung as CEO
Monday, 10 Apr 2017 08:15am EDT 

Axovant Sciences Ltd : Axovant Sciences announces appointment of Dr. David Hung as chief executive officer and expansion of board of directors . Axovant Sciences Ltd - Mindset study results for intepirdine in mild-to-moderate Alzheimer's disease expected in late September 2017 . Axovant Sciences Ltd says Mindset study results for intepirdine in mild-to-moderate Alzheimer's disease expected in late September 2017 . Vivek Ramaswamy to remain on board of directors and assume full-time role as CEO of parent company Roivant sciences . Axovant Sciences Ltd- also announced appointment of Marion Mccourt as president and chief operating officer . Axovant Sciences Ltd - Hung, who also joined Axovant's board of directors, succeeds founding chief executive officer Vivek Ramaswamy . Former medivation directors Kate Falberg and Tony Vernon appointed to board of directors .Axovant Sciences Ltd - David Hung has been named chief executive officer of Axovant Sciences, effective April 7, 2017.  Full Article

CORRECTED-BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study

* AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT